<DOC>
	<DOCNO>NCT00408226</DOCNO>
	<brief_summary>To determine toxicity , maximum tolerate dose ( MTD ) recommend phase 2 dose MKC-1 administer orally , twice daily 14 day follow 7 day without dose , combination pemetrexed ( deliver recommend single agent dose ) patient advance solid tumor malignancy . Also , determine antitumor activity , base objective response rate median Progression Free Survival ( `` PFS '' ) , oral MKC-1 , administer schedule combination pemetrexed patient non small cell lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Safety Study MKC-1 Combined With Pemetrexed Treat Advanced Cancer Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Patients must satisfy criterion base portion study consider enrollment : Dose Escalating Phase : Patients advance solid tumor malignancy singleagent pemetrexed therapy would contraindicate . Measurable disease require . Phase 2 portion : Current diagnosis Stage IIIb ( due malignant pleural effusion supraclavicular lymph node involvement ) Stage IV histologically and/or cytologically proven nonsmall cell lung cancer accord stag system American Joint Committee Cancer . ( ) Patient receive maximally feasible surgical resection and/or radiotherapy initial disease . ( ii ) Either disease progression follow treatment one prior chemotherapy regimen use treatment metastatic disease disease progression follow adjuvant/neoadjuvant therapy within one year last dose chemotherapy ( patient disease progression follow adjuvant/neoadjuvant therapy &gt; 1 year last dose chemotherapy ) disease progression follow one additional chemotherapy regimen metastatic disease . ( iii ) Radiographic physical examination evidence least one site unidimensionallymeasurable disease , use RECIST criterion disease assess within 28 day prior treatment initiation . 2 . Age ≥ 18 year . 3 . ECOG performance status 0 1 . 4 . All acute toxicity prior chemotherapy , surgery radiotherapy must resolve NCI CTCAE Grade ≤ 1 , except alopecia . 5 . The following laboratory result , within 10 day MKC1 administration : Hemoglobin ≥ 9 g/dL Absolute neutrophil count ≥ 1.5 x 109/L Platelet count ≥ 75 x 109/L Serum creatinine ≤ 1.5 x ULN ( upper limit normal ) Creatinine clearance ≥ 45 mL/min AST ≤ 2.5 x ULN Serum albumin ≥ LLN ( low limit normal ) 3.5 g/dL Total bilirubin ≤ ULN 6 . Signed informed consent . 1 . Preexisting hepatomegaly disease measure ≥ 2 cm costal margin , secondary malignancy . 2 . Uncontrolled pleural effusion ( define 2 pleuracenteses within 4 week first dose study drug ) 3 . Administration cancerspecific therapy within follow period prior study drug initiation : le 4 week prior : major surgery ( include placement venous access device biopsy ) investigational therapy ; le 3 week prior : radiation therapy chemotherapy ( except oral EGFR receptor tyrosine kinase inhibitor ( ) ; le 2 week prior : oral EGFR receptor tyrosine kinase inhibitor ( ) . 4 . Pregnant breastfeed woman . Female patient must postmenopausal , surgically sterile must agree use physical method contraception . Female patient childbearing potential must negative pregnancy test within 10 day first MKC1 administration . Male patient must surgically sterile agree use acceptable method contraception . 5 . Known CNS leptomeningeal metastasis unless treat , clinically stable require steroid . 6 . Clinical evidence bowel obstruction , active uncontrolled malabsorption syndrome history total gastrectomy . 7 . Uncontrolled hypercalcemia ( serum calciumcorrected &gt; 12 mg/dL ) 8 . Serious cardiac condition ( Class III/IV congestive heart failure accord New York Heart Association classification ) ; document acute myocardial infarction within previous 6 month . 9 . Any medical condition , investigator 's opinion , would impose excessive risk patient . Examples condition include congestive heart failure Class III IV NYHA classification , infection require parenteral oral antiinfective treatment , alter mental status psychiatric condition would interfere understand informed consent . 10 . Patients active secondary malignancy . 11 . Treatment antiretroviral therapy metabolize CYP3A4 ( include indinavir , nelfinavir , ritonavir saquinavir ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
</DOC>